Percutaneous Cardiovascular Procedures with Intraluminal Device DRG Reimbursement

Summary & Overview

Percutaneous Cardiovascular Procedures with Intraluminal Device without MCC: Inpatient Reimbursement Overview

DRG 322 encompasses percutaneous cardiovascular procedures with intraluminal device placement performed without a Major Complication or Comorbidity, covering common inpatient coronary interventions. This grouping matters for inpatient reimbursement because it standardizes payment for these procedures under Medicare, reflecting expected resource utilization and influencing hospital revenue for cardiovascular cases.

Percutaneous Cardiovascular Procedures with Intraluminal Device without MCCDRG Percutaneous Cardiovascular Procedures with Intraluminal Device without MCCDRG 322Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyPercutaneous Coronary InterventionStent placement

DRG 322 Overview

DRG 322 covers hospital admissions for percutaneous cardiovascular procedures using intraluminal devices without a Major Complication or Comorbidity and typically includes elective coronary interventions such as percutaneous transluminal coronary angioplasty with stent placement when no severe comorbid conditions are present. This Diagnosis-Related Group groups cases by resource use and procedural complexity to determine Medicare payment for inpatient stays. It matters for Medicare payment because it allocates a specific inpatient reimbursement relative to other cardiovascular procedure groups, influencing hospital billing and case-mix considerations. Understanding the clinical scope and grouping criteria helps clarify which admissions qualify for this payment category.

National Payment Rates

Payer rates for DRG 322 range from about $14K (BCBS) to $29K (Cigna) in mean payments, with payer medians spanning roughly $6K to $29K across the four payers shown; Anthem and Aetna have mean values near $17K and $28K respectively. The widest spread between payer means is approximately $15K (BCBS to Cigna). See the table and chart below for detailed percentile and distribution information by payer.

Mean Rates by Payer — National — DRG 322

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska for DRG 322, payer rates span a wide range from approximately $7.5K at the low end up to $75K at the high end across payers. Cigna stands out with substantially higher central tendency (median $42K, mean $44K) compared with BCBS and Anthem (median $27K, mean $26K). This distribution displays a pronounced upper tail relative to national medians. See the table and chart below for the payer-level breakdown.

Key Insights for Alaska

Highest payer: Cigna (median $42K, mean $44K) while lowest reported payers: Blue Cross Blue Shield and Anthem (median $27K, mean $26K).
Alaska rates range from about $7.5K (min observed for BCBS/Anthem) up to $75K (max for Cigna), a notably wider and higher upper tail versus national medians where typical medians are much lower (national medians around $13K–$29K depending on payer).

Clinical Trials

Acute procedural optimization studies: randomized or pragmatic trials focusing on intraprocedural techniques and adjunctive pharmacotherapy during percutaneous cardiovascular interventions (PCI) for patients with symptomatic coronary artery disease or acute coronary syndromes who do not have major comorbid complications (no MCC). These studies enroll the typical inpatient population receiving percutaneous intraluminal devices (stents, balloons, atherectomy) and compare procedural endpoints such as acute vessel patency, peri-procedural myocardial injury, bleeding, and short-term complications. Results inform cardiology teams and hospital payers about best practices that reduce length of stay, complication-related costs, and readmission risk for DRG 322 patients.
Comparative effectiveness and device selection studies: cohort studies or randomized trials comparing types of intraluminal devices or implantation strategies (for example, newer-generation stent platforms versus standard platforms, or different deployment methods) in elective or urgent PCI populations without major complications. These studies focus on mid-term outcomes like restenosis, target lesion revascularization, and resource use (repeat procedures, imaging, outpatient follow-up) in patients assigned to DRG 322-level care. Findings are relevant to providers for device choice and to payers and hospitals for cost-effectiveness and bundle payment considerations, because device selection can materially impact downstream utilization.
Post-discharge outcomes and care pathway research: observational and interventional studies evaluating transitional care, secondary prevention adherence, and outpatient monitoring strategies after hospital discharge for patients treated with percutaneous intraluminal devices who did not experience major complications. These studies target readmission rates, adherence to antiplatelet therapy and cardiac rehabilitation participation, and patient-reported outcomes in the typical post-DRG 322 cohort. Evidence from these studies helps health systems and payers design discharge protocols and outpatient management that reduce avoidable returns to inpatient care and improve long-term value for this population.

Coronary Bypass with PTCA without MCC: Inpatient Reimbursement Overview

293-HEART-FAILURE-AND-SHOCK-WITHOUT-CC-MCC

Heart Failure and Shock without CC/MCC: Inpatient Reimbursement Overview

300-PERIPHERAL-VASCULAR-DISORDERS-WITH-CC

Peripheral Vascular Disorders with CC: Inpatient Reimbursement Overview

233-CORONARY-BYPASS-WITH-CARDIAC-CATHETERIZATION-OR-OPEN-ABLATION-WITH-MCC

Coronary Bypass with Cardiac Catheterization or Open Ablation with MCC: Inpatient Reimbursement Overview

301-PERIPHERAL-VASCULAR-DISORDERS-WITHOUT-CC-MCC

Peripheral Vascular Disorders without CC/MCC: Inpatient Reimbursement Overview

276-CARDIAC-DEFIBRILLATOR-IMPLANT-WITH-MCC-OR-CAROTID-SINUS-NEUROSTIMULATOR

Cardiac Defibrillator Implant with MCC or Carotid Sinus Neurostimulator: Inpatient Reimbursement Overview

315-OTHER-CIRCULATORY-SYSTEM-DIAGNOSES-WITH-CC

Other Circulatory System Diagnoses with CC: Inpatient Reimbursement Overview

311-ANGINA-PECTORIS

Angina Pectoris: Inpatient Reimbursement Overview

241-AMPUTATION-FOR-CIRCULATORY-SYSTEM-DISORDERS-EXCEPT-UPPER-LIMB-AND-TOE-WITHOUT-CC-MCC

Amputation for Circulatory System Disorders Except Upper Limb and Toe without CC/MCC: Inpatient Reimbursement Overview

287-CIRCULATORY-DISORDERS-EXCEPT-AMI-WITH-CARDIAC-CATHETERIZATION-WITHOUT-MCC

Circulatory Disorders Except AMI, with Cardiac Catheterization without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Percutaneous Cardiovascular Procedures with Intraluminal Device without MCC: Inpatient Reimbursement Overview

DRG 322 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes